NYSE · AZN
AstraZeneca financials
$164.21−1.17%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '16 Jun 30 | Q1 '16 Mar 31 | Q4 '15 Dec 31 | Q3 '15 Sep 30 | Q2 '15 Jun 30 | Q1 '15 Mar 31 | Q4 '14 Dec 31 | Q3 '14 Sep 30 | Q2 '14 Jun 30 | Q1 '14 Mar 31 | Q4 '13 Dec 31 | Q3 '13 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.60B | $6.12B | $6.40B | $5.95B | $6.31B | $6.06B | $6.72B | $6.61B | $6.45B | $6.46B | $6.84B | $6.25B |
| Gross profit | $4.45B | $5.04B | $5.03B | $4.83B | $5.16B | $4.71B | $4.96B | $5.11B | $5.07B | $4.93B | $5.33B | $4.93B |
| Gross margin | 79.4% | 82.3% | 78.6% | 81.2% | 81.8% | 77.8% | 73.9% | 77.3% | 78.6% | 76.4% | 77.9% | 78.9% |
| Operating income | $303.0M | $1.04B | $1.09B | $1.17B | $923.0M | $933.0M | -$349.0M | $541.0M | $1.11B | $836.0M | -$591.0M | $1.71B |
| Net income | -$3.0M | $646.0M | $808.0M | $770.0M | $697.0M | $550.0M | -$321.0M | $254.0M | $796.0M | $504.0M | -$524.0M | $1.25B |
| Net margin | −0.1% | 10.6% | 12.6% | 13.0% | 11.1% | 9.1% | −4.8% | 3.8% | 12.3% | 7.8% | −7.7% | 19.9% |
| Diluted EPS | $0.00 | $0.51 | $0.64 | $0.60 | $0.55 | $0.44 | $-0.25 | $0.20 | $0.32 | $0.20 | $-0.42 | $0.49 |
| EBITDA | $890.0M | $1.61B | $1.09B | $1.74B | $1.64B | $1.78B | -$349.0M | $1.39B | $1.11B | $1.55B | -$591.0M | $2.09B |
| Operating cash flow | $181.0M | $1.19B | $571.0M | $1.75B | $1.08B | -$72.0M | $1.84B | $1.95B | $2.08B | $1.19B | $2.48B | $1.12B |
| Free cash flow | -$136.0M | $926.0M | $117.0M | $1.37B | $810.0M | -$299.0M | $1.45B | $1.71B | $1.88B | $1.00B | $2.10B | $990.0M |
| Diluted shares | 1,265.0M | 1,265.0M | 1,265.0M | 1,265.0M | 1,265.0M | 1,265.0M | 1,264.0M | 1,264.0M | 2,528.0M | 2,524.0M | 1,254.0M | 2,508.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.71B | $5.49B | $5.84B | $6.17B | $6.33B | $7.83B |
| Short-term investments | $30.0M | $166.0M | $122.0M | $239.0M | $69.0M | $160.0M |
| Total debt | $27.82B | $28.84B | $27.49B | $28.28B | $29.79B | $19.70B |
| Total assets | $114.07B | $104.03B | $101.12B | $96.48B | $105.36B | $66.73B |
| Total liabilities | $65.36B | $63.16B | $61.95B | $59.42B | $66.08B | $51.09B |
| Shareholders' equity | $48.72B | $40.87B | $39.17B | $37.06B | $39.29B | $15.64B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology